Anuradha Banerjee, MD

Education
M.D., 1992 - School of Medicine, Tulane University
Websites
Publications
  1. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
  2. A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study.
  3. Nutritional status and concomitant factors of stunting among pre-school children in Malda, India: A micro-level study using a multilevel approach.
  4. Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
  5. Rate of radiation-induced microbleed formation on 7T MRI relates to cognitive impairment in young patients treated with radiation therapy for a brain tumor.
  6. Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
  7. Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition.
  8. Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features.
  9. Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features.
  10. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas.
  11. Acupressure to Reduce Treatment-Related Symptoms for Children With Cancer and Recipients of Hematopoietic Stem Cell Transplant: Protocol for a Randomized Controlled Trial.
  12. High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication-a comprehensive clinical, radiographic, pathologic, and genomic analysis.
  13. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
  14. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.
  15. Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma.
  16. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
  17. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.
  18. Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts.
  19. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.
  20. The genetic landscape of gliomas arising after therapeutic radiation.
  21. The University of California, San Francisco Documentation System for Retinoblastoma: Preparing to Improve Staging Methods for This Disease.
  22. The genetic landscape of ganglioglioma.
  23. Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors.
  24. Early detection of recurrent medulloblastoma: the critical role of diffusion-weighted imaging.
  25. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation.
  26. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
  27. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
  28. Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients.
  29. Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors.
  30. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
  31. Metastatic Diffuse Intrinsic Pontine Glioma to the Peritoneal Cavity Via Ventriculoperitoneal Shunt: Case Report and Literature Review.
  32. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
  33. Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.
  34. Pure germinomas of the central nervous system: treatment strategies and outcomes.
  35. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
  36. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
  37. Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution.
  38. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children.
  39. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
  40. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment.
  41. Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001).
  42. The superiority of conservative resection and adjuvant radiation for craniopharyngiomas.
  43. An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing.
  44. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy.
  45. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
  46. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.
  47. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.
  48. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
  49. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
  50. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.
  51. High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system.
  52. A human brainstem glioma xenograft model enabled for bioluminescence imaging.
  53. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
  54. Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors.
  55. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
  56. The value of tandem CSF/MRI evaluation for predicting disseminated disease in childhood central nervous system neoplasms.
  57. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Cons
  58. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
  59. Medulloblastoma simulating acute myeloid leukemia: case report with a review of "myeloid antigen" expression in nonhematopoietic tissues and tumors.
  60. The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas.
  61. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.
  62. Can mouse models for brain tumors inform treatment in pediatric patients?
  63. Clonal evolution in marrows of patients with Shwachman-Diamond syndrome: a prospective 5-year follow-up study.
  64. Pediatric acute blastic natural killer cell leukemia.